Update on Emerging Treatment Options for Primary Biliary Cholangitis

Maria T Aguilar,1 David M Chascsa2 1Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; 2Department of Gastroenterology & Hepatology, Mayo Clinic, Phoenix, AZ, USACorrespondence: Maria T Aguilar Email aguilar.maria1@mayo.eduAbstract: Primary biliary cholang...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aguilar MT, Chascsa DM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	primary biliary cholangitis obeticholic acid fibrate Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/a79fd9431735437a96d7dd425b5d7d37
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a79fd9431735437a96d7dd425b5d7d37
record_format	dspace
spelling	oai:doaj.org-article:a79fd9431735437a96d7dd425b5d7d372021-12-02T09:14:05ZUpdate on Emerging Treatment Options for Primary Biliary Cholangitis1179-1535https://doaj.org/article/a79fd9431735437a96d7dd425b5d7d372020-05-01T00:00:00Zhttps://www.dovepress.com/update-on-emerging-treatment-options-for-primary-biliary-cholangitis-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Maria T Aguilar,1 David M Chascsa2 1Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; 2Department of Gastroenterology & Hepatology, Mayo Clinic, Phoenix, AZ, USACorrespondence: Maria T Aguilar Email aguilar.maria1@mayo.eduAbstract: Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis or cirrhosis. Treatment options are currently limited. Ursodeoxycholic acid (UDCA) remains first-line therapy and has been proven to normalize serum biochemistries, halt histologic disease progression, and lead to patient survival comparable to the general population. Obeticholic acid (OCA) was recently approved as adjunct therapy in PBC patients with inadequate response or intolerance to UDCA. However, OCA has been associated with worsening pruritus in clinical studies which may limit its use in this patient population. Several studies are currently underway to address the lack of treatment options for PBC. Of these, fibrates, which have been used in Japan for over a decade, have produced promising results. Furthermore, as currently approved therapies for PBC do not address the potentially debilitating clinical symptoms of PBC such as pruritus and fatigue, supplemental therapy is often required for symptom control.Keywords: primary biliary cholangitis, obeticholic acid, fibrateAguilar MTChascsa DMDove Medical Pressarticleprimary biliary cholangitisobeticholic acidfibrateDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 12, Pp 69-77 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	primary biliary cholangitis obeticholic acid fibrate Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	primary biliary cholangitis obeticholic acid fibrate Diseases of the digestive system. Gastroenterology RC799-869 Aguilar MT Chascsa DM Update on Emerging Treatment Options for Primary Biliary Cholangitis
description	Maria T Aguilar,1 David M Chascsa2 1Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; 2Department of Gastroenterology & Hepatology, Mayo Clinic, Phoenix, AZ, USACorrespondence: Maria T Aguilar Email aguilar.maria1@mayo.eduAbstract: Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis or cirrhosis. Treatment options are currently limited. Ursodeoxycholic acid (UDCA) remains first-line therapy and has been proven to normalize serum biochemistries, halt histologic disease progression, and lead to patient survival comparable to the general population. Obeticholic acid (OCA) was recently approved as adjunct therapy in PBC patients with inadequate response or intolerance to UDCA. However, OCA has been associated with worsening pruritus in clinical studies which may limit its use in this patient population. Several studies are currently underway to address the lack of treatment options for PBC. Of these, fibrates, which have been used in Japan for over a decade, have produced promising results. Furthermore, as currently approved therapies for PBC do not address the potentially debilitating clinical symptoms of PBC such as pruritus and fatigue, supplemental therapy is often required for symptom control.Keywords: primary biliary cholangitis, obeticholic acid, fibrate
format	article
author	Aguilar MT Chascsa DM
author_facet	Aguilar MT Chascsa DM
author_sort	Aguilar MT
title	Update on Emerging Treatment Options for Primary Biliary Cholangitis
title_short	Update on Emerging Treatment Options for Primary Biliary Cholangitis
title_full	Update on Emerging Treatment Options for Primary Biliary Cholangitis
title_fullStr	Update on Emerging Treatment Options for Primary Biliary Cholangitis
title_full_unstemmed	Update on Emerging Treatment Options for Primary Biliary Cholangitis
title_sort	update on emerging treatment options for primary biliary cholangitis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a79fd9431735437a96d7dd425b5d7d37
work_keys_str_mv	AT aguilarmt updateonemergingtreatmentoptionsforprimarybiliarycholangitis AT chascsadm updateonemergingtreatmentoptionsforprimarybiliarycholangitis
_version_	1718398202662617088

Update on Emerging Treatment Options for Primary Biliary Cholangitis

Ejemplares similares